Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDGL Stock Forecast 2026-2027
$467.28
Current Price
$10.77B
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MDGL Price Targets
+106.3%
To High Target of $964.00
+39.0%
To Median Target of $649.50
+17.7%
To Low Target of $550.00
MDGL Price Momentum
+3.2%
1 Week Change
-8.4%
1 Month Change
+66.7%
1 Year Change
-19.8%
Year-to-Date Change
-24.0%
From 52W High of $615.00
+69.9%
From 52W Low of $275.00
📊 TOP ANALYST CALLS
Did MDGL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Madrigal is one of their latest high-conviction picks.
Latest MDGL Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, MDGL has a bullish consensus with a median price target of $649.50 (ranging from $550.00 to $964.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $467.28, the median forecast implies a 39.0% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDGL Analyst Ratings
11
Buy
2
Hold
0
Sell
MDGL Price Target Range
Low
$550.00
Average
$649.50
High
$964.00
Current: $467.28
Latest MDGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $709.00 |
| May 7, 2026 | Canaccord Genuity | Edward Nash | Buy | Maintains | $578.00 |
| May 7, 2026 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $649.00 |
| May 6, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $620.00 |
| Feb 20, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Jan 28, 2026 | Barclays | Overweight | Initiates | $N/A | |
| Jan 20, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Dec 19, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Dec 11, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 20, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 19, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Nov 13, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Cantor Fitzgerald | Overweight | Upgrade | $N/A | |
| Nov 5, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Nov 3, 2025 | B of A Securities | Neutral | Upgrade | $N/A | |
| Oct 15, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 15, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Oct 10, 2025 | Oppenheimer | Outperform | Maintains | $N/A |
Madrigal Pharmaceuticals, Inc. (MDGL) Competitors
The following stocks are similar to Madrigal based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Madrigal Pharmaceuticals, Inc. (MDGL) Financial Data
Madrigal Pharmaceuticals, Inc. has a market capitalization of $10.77B with a P/E ratio of -36.4x. The company generates $1.13B in trailing twelve-month revenue with a -27.3% profit margin.
Revenue growth is +126.8% quarter-over-quarter, while maintaining an operating margin of -29.8% and return on equity of -49.3%.
Valuation Metrics
Market Cap
$10.77B
Enterprise Value
$10.76B
P/E Ratio
-36.4x
PEG Ratio
17.2x
Price/Sales
9.9x
Growth & Margins
Revenue Growth (YoY)
+126.8%
Gross Margin
+91.4%
Operating Margin
-29.8%
Net Margin
-27.3%
EPS Growth
+126.8%
Financial Health
Cash/Price Ratio
+7.5%
Current Ratio
3.5x
Debt/Equity
63.9x
ROE
-49.3%
ROA
-17.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Madrigal Pharmaceuticals, Inc. (MDGL) Business Model
About Madrigal Pharmaceuticals, Inc.
What They Do
Develops therapeutics for liver diseases.
Business Model
Madrigal Pharmaceuticals generates revenue by developing and commercializing innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH) and related liver conditions. Its lead product, Rezdiffra, is the first FDA-approved treatment in this category, providing a significant market opportunity as the company expands its pipeline and licensing agreements.
Additional Information
Madrigal is headquartered in West Conshohocken, Pennsylvania, and has a focus on addressing unmet medical needs in cardiovascular, metabolic, and liver diseases. The company has established a strong presence in the growing metabolic liver disease market and is actively involved in rapid commercialization efforts in both the United States and Europe.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
915
CEO
Mr. William J. Sibold
Country
United States
IPO Year
2007
Website
www.madrigalpharma.comMadrigal Pharmaceuticals, Inc. (MDGL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Jun 08, 2026
By Zacks Equity Research
Analyst Blog Plus
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Madrigal (MDGL) reported earnings 30 days ago. Investors should monitor upcoming developments and stock performance for future insights.
Why It Matters
Madrigal's recent earnings report could signal future performance trends, impacting stock valuation and investor sentiment as they assess growth potential.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in the Goldman Sachs Health Care Conference on June 10, 2026, at 11:20 A.M.
Why It Matters
Madrigal Pharmaceuticals' participation in a major healthcare conference may indicate upcoming developments or announcements, potentially impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
4 days ago
Quick Summary
Madrigal Pharmaceuticals granted equity awards to 20 new non-executive employees as part of its 2025 Inducement Plan, approved by its Compensation Committee.
Why It Matters
The granting of equity awards to new employees can enhance talent acquisition and retention, potentially driving innovation and growth, which may positively impact Madrigal's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Madrigal Pharmaceuticals' Rezdiffra targets MASH with a growing U.S. TAM. While it faces competition from Novo Nordisk, it has a near-term advantage and potential for significant revenue growth.
Why It Matters
Madrigal's Rezdiffra targets a growing market with potential for significant revenue. However, competition from established players poses risks to its long-term success.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Madrigal Pharmaceuticals' Rezdiffra (resmetirom) shows promise as a foundational therapy for MASH, improving cardiovascular and liver-related risk markers in recent analyses.
Why It Matters
Positive clinical data for Rezdiffra enhances Madrigal Pharmaceuticals' growth prospects, potentially increasing market confidence and stock value as it addresses significant health risks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Madrigal Pharmaceuticals will present data on Rezdiffra (resmetirom) at the EASL Congress 2026, focusing on lipid profile improvements and risk score enhancements in MASH patients.
Why It Matters
Positive data on Rezdiffra's efficacy in improving lipid profiles and predicting fibrosis could boost Madrigal Pharmaceuticals' stock, indicating strong market potential and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDGL Stock
What is Madrigal Pharmaceuticals, Inc.'s (MDGL) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Madrigal Pharmaceuticals, Inc. (MDGL) has a median price target of $649.50. The highest price target is $964.00 and the lowest is $550.00.
Is MDGL stock a good investment in 2026?
According to current analyst ratings, MDGL has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $467.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDGL stock?
Wall Street analysts predict MDGL stock could reach $649.50 in the next 12 months. This represents a 39.0% increase from the current price of $467.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Madrigal Pharmaceuticals, Inc.'s business model?
Madrigal Pharmaceuticals generates revenue by developing and commercializing innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH) and related liver conditions. Its lead product, Rezdiffra, is the first FDA-approved treatment in this category, providing a significant market opportunity as the company expands its pipeline and licensing agreements.
What is the highest forecasted price for MDGL Madrigal Pharmaceuticals, Inc.?
The highest price target for MDGL is $964.00 from at , which represents a 106.3% increase from the current price of $467.28.
What is the lowest forecasted price for MDGL Madrigal Pharmaceuticals, Inc.?
The lowest price target for MDGL is $550.00 from at , which represents a 17.7% increase from the current price of $467.28.
What is the overall MDGL consensus from analysts for Madrigal Pharmaceuticals, Inc.?
The overall analyst consensus for MDGL is bullish. Out of 5 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $649.50.
How accurate are MDGL stock price projections?
Stock price projections, including those for Madrigal Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:16 AM UTC